{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:10:23Z","timestamp":1787022623890,"version":"build-2736575974"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2023-0001_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The Peritoneal Surface Oncology Group International (PSOGI) consensus subdivided pseudomyxoma peritonei (PMP) into four groups according to histopathological features. The aim of this paper is to report survival outcomes after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) from a national referral centre and to correlate the PSOGI classification with survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0001_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study of a prospectively maintained database was performed. Consecutive patients treated with CRS\u00a0+\u00a0HIPEC for PMP of appendiceal origin were included (September-2013 to December-2021). Pathological features of the peritoneal disease were used to classify patients into the four groups proposed by PSOGI. Survival analysis was performed to evaluate the correlation of pathology on overall survival (OS) and disease-free survival (DFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0001_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 104 patients were identified; 29.6\u202f% were reclassified as acellular mucin (AM), 43.9\u202f% as low-grade mucinous carcinoma peritonei (LGMCP), 22.4\u202f% as high-grade MCP (HGMCP) and 4.1\u202f% as HGMCP with signet ring cells (HGMCP-SRC). Median PCI and rate of optimal cytoreduction were 19 and 82.7\u202f%, respectively. Median OS and DFS were not reached, 5-year OS and DFS were 88.6(SD 0.04)\u202f% and 61.6(SD 0.06)\u202f%, respectively. Log-Rank test revealed significant differences in terms of OS and DFS across the different histological subgroups (p&lt;0.001 in both cases). However, histology did not retain its significance in the multivariate analysis for OS or DFS (p=0.932 and p=0.872, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2023-0001_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Survival outcomes after CRS\u00a0+\u00a0HIPEC for PMP are excellent. The PSOGI pathological classification correlates with OS and DFS, but differences were not significant at multivariate analysis when adjusted for other prognostic factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2023-0001","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T09:07:33Z","timestamp":1682672853000},"page":"65-74","source":"Crossref","is-referenced-by-count":9,"title":["Correlation between PSOGI pathological classification and survival outcomes of patients with pseudomyxoma peritonei treated using cytoreductive surgery and HIPEC: national referral centre experience and literature review"],"prefix":"10.1515","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-910X","authenticated-orcid":false,"given":"Lorena","family":"Mart\u00edn-Rom\u00e1n","sequence":"first","affiliation":[{"name":"Department of Surgery , National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enda","family":"Hannan","sequence":"additional","affiliation":[{"name":"Department of Surgery , National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Faraz Khan","sequence":"additional","affiliation":[{"name":"Department of Surgery , National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Sophia","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Surgery , National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Surgery , National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Aird","sequence":"additional","affiliation":[{"name":"Department of Pathology , Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Moran","sequence":"additional","affiliation":[{"name":"Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital , Basingstoke , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Mulsow","sequence":"additional","affiliation":[{"name":"Department of Surgery , National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"key":"2023060816410815274_j_pp-2023-0001_ref_001","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994;219:109\u201311. https:\/\/doi.org\/10.1097\/00000658-199402000-00001.","DOI":"10.1097\/00000658-199402000-00001"},{"key":"2023060816410815274_j_pp-2023-0001_ref_002","doi-asserted-by":"crossref","unstructured":"Amin, MB, Greene, FL, Edge, SB, Compton, CC, Gershenwald, JE, Brookland, RK, et al.. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging. CA Cancer J Clin 2017;67:93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","DOI":"10.3322\/caac.21388"},{"key":"2023060816410815274_j_pp-2023-0001_ref_003","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69\u201376. https:\/\/doi.org\/10.1016\/s1470-2045(05)70539-8.","DOI":"10.1016\/S1470-2045(05)70539-8"},{"key":"2023060816410815274_j_pp-2023-0001_ref_004","doi-asserted-by":"crossref","unstructured":"Ronnett, BM, Zahn, CM, Kurman, RJ, Kass, ME, Sugarbaker, PH, Shmookler, BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \u2018pseudomyxoma peritonei. Am J Surg Pathol 1995;19:1390\u2013408. https:\/\/doi.org\/10.1097\/00000478-199512000-00006.","DOI":"10.1097\/00000478-199512000-00006"},{"key":"2023060816410815274_j_pp-2023-0001_ref_005","doi-asserted-by":"crossref","unstructured":"Misdraji, J, Yantiss, RK, Graeme-Cook, FM, Balis, UJ, Young, RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003;27:1089\u2013103. https:\/\/doi.org\/10.1097\/00000478-200308000-00006.","DOI":"10.1097\/00000478-200308000-00006"},{"key":"2023060816410815274_j_pp-2023-0001_ref_006","doi-asserted-by":"crossref","unstructured":"Bradley, RF, Stewart, JH, Russell, GB, Levine, EA, Geisinger, KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551\u20139. https:\/\/doi.org\/10.1097\/01.pas.0000202039.74837.7d.","DOI":"10.1097\/01.pas.0000202039.74837.7d"},{"key":"2023060816410815274_j_pp-2023-0001_ref_007","doi-asserted-by":"crossref","unstructured":"Carr, NJ, Cecil, TD, Mohamed, F, Sobin, LH, Sugarbaker, PH, Gonz\u00e1lez-Moreno, S, et al.. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the peritoneal surface Oncology group international (PSOGI) modified delphi process. Am J Surg Pathol 2016;40:14\u201326. https:\/\/doi.org\/10.1097\/pas.0000000000000535.","DOI":"10.1097\/PAS.0000000000000535"},{"key":"2023060816410815274_j_pp-2023-0001_ref_008","doi-asserted-by":"crossref","unstructured":"Baratti, D, Kusamura, S, Milione, M, Bruno, F, Guaglio, M, Deraco, M. Validation of the recent PSOGI pathological classification of pseudomyxoma peritonei in a single-center series of 265 patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2018;25:404\u201313. https:\/\/doi.org\/10.1245\/s10434-017-6252-1.","DOI":"10.1245\/s10434-017-6252-1"},{"key":"2023060816410815274_j_pp-2023-0001_ref_009","doi-asserted-by":"crossref","unstructured":"Govaerts, K, Lurvink, RJ, De Hingh, IHJT, Van der Speeten, K, Villeneuve, L, Kusamura, S, et al.. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2020. https:\/\/doi.org\/10.1016\/j.ejso.2020.02.012.","DOI":"10.1016\/j.ejso.2020.02.012"},{"key":"2023060816410815274_j_pp-2023-0001_ref_010","doi-asserted-by":"crossref","unstructured":"Huang, Y, Alzahrani, NA, Chua, TC, Morris, DL. Histological subtype remains a significant prognostic factor for survival outcomes in patients with appendiceal mucinous neoplasm with peritoneal dissemination. Dis Colon Rectum 2017;60:360\u20137. https:\/\/doi.org\/10.1097\/dcr.0000000000000719.","DOI":"10.1097\/DCR.0000000000000719"},{"key":"2023060816410815274_j_pp-2023-0001_ref_011","doi-asserted-by":"crossref","unstructured":"Power, JW, Dempsey, PJ, Yates, A, Fenlon, H, Mulsow, J, Shields, C, et al.. Peritoneal malignancy: anatomy, pathophysiology and an update on modern day imaging. Br J Radiol 2022;95:20210217. https:\/\/doi.org\/10.1259\/bjr.20210217.","DOI":"10.1259\/bjr.20210217"},{"key":"2023060816410815274_j_pp-2023-0001_ref_012","doi-asserted-by":"crossref","unstructured":"Jacquet, P, Sugarbaker, PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2023060816410815274_j_pp-2023-0001_ref_013","doi-asserted-by":"crossref","unstructured":"Van der Speeten, K, Stuart, OA, Sugarbaker, PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J Sudbury Mass 2009;15:216\u201324. https:\/\/doi.org\/10.1097\/ppo.0b013e3181a58d95.","DOI":"10.1097\/PPO.0b013e3181a58d95"},{"key":"2023060816410815274_j_pp-2023-0001_ref_014","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Peritonectomy procedures. Surg Oncol Clin 2003;12:703\u201327. https:\/\/doi.org\/10.1016\/s1055-3207(03)00048-6.","DOI":"10.1016\/S1055-3207(03)00048-6"},{"key":"2023060816410815274_j_pp-2023-0001_ref_015","doi-asserted-by":"crossref","unstructured":"Dindo, D, Demartines, N, Clavien, PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"2023060816410815274_j_pp-2023-0001_ref_016","doi-asserted-by":"crossref","unstructured":"Valasek, MA, Pai, RK. An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms. Adv Anat Pathol 2018;25:38\u201360. https:\/\/doi.org\/10.1097\/pap.0000000000000178.","DOI":"10.1097\/PAP.0000000000000178"},{"key":"2023060816410815274_j_pp-2023-0001_ref_017","doi-asserted-by":"crossref","unstructured":"Carr, NJ. Updates in appendix pathology: the precarious cutting edge. Surg Pathol Clin 2020;13:469\u201384. https:\/\/doi.org\/10.1016\/j.path.2020.05.006.","DOI":"10.1016\/j.path.2020.05.006"},{"key":"2023060816410815274_j_pp-2023-0001_ref_018","doi-asserted-by":"crossref","unstructured":"Shetty, S, Natarajan, B, Thomas, P, Govindarajan, V, Sharma, P, Loggie, B. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg 2013;79:1171\u20136. https:\/\/doi.org\/10.1177\/000313481307901120.","DOI":"10.1177\/000313481307901120"},{"key":"2023060816410815274_j_pp-2023-0001_ref_019","doi-asserted-by":"crossref","unstructured":"Davison, JM, Choudry, HA, Pingpank, JF, Ahrendt, SA, Holtzman, MP, Zureikat, AH, et al.. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol Off J U S Can Acad Pathol Inc 2014;27:1521\u201339. https:\/\/doi.org\/10.1038\/modpathol.2014.37.","DOI":"10.1038\/modpathol.2014.37"},{"key":"2023060816410815274_j_pp-2023-0001_ref_020","doi-asserted-by":"crossref","unstructured":"Rufi\u00e1n-Andujar, B, Valenzuela-Molina, F, Rufi\u00e1n-Pe\u00f1a, S, Casado-Adam, \u00c1, S\u00e1nchez-Hidalgo, JM, Rodr\u00edguez-Ortiz, L, et al.. From the Ronnett to the PSOGI classification system for pseudomyxoma peritonei: a validation study. Ann Surg Oncol 2021;28:2819\u201327. https:\/\/doi.org\/10.1245\/s10434-020-09560-w.","DOI":"10.1245\/s10434-020-09560-w"},{"key":"2023060816410815274_j_pp-2023-0001_ref_021","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Rom\u00e1n, L, Lozano, P, G\u00f3mez, Y, Fern\u00e1ndez-Ace\u00f1ero, MJ, Vasquez, W, Palencia, N, et al.. Which classification system defines best prognosis of mucinous neoplasms of the appendix with peritoneal dissemination: TNM vs. PSOGI? J Clin Pathol 2021;76:266\u201373. https:\/\/doi.org\/10.1136\/jclinpath-2021-207883.","DOI":"10.1136\/jclinpath-2021-207883"},{"key":"2023060816410815274_j_pp-2023-0001_ref_022","doi-asserted-by":"crossref","unstructured":"Munoz-Zuluaga, C, Sardi, A, King, MC, Nieroda, C, Sittig, M, MacDonald, R, et al.. Outcomes in peritoneal dissemination from signet ring cell carcinoma of the appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2019;26:473\u201381. https:\/\/doi.org\/10.1245\/s10434-018-7007-3.","DOI":"10.1245\/s10434-018-7007-3"},{"key":"2023060816410815274_j_pp-2023-0001_ref_023","doi-asserted-by":"crossref","unstructured":"Lee, JL, Kim, M, Kim, J, Kim, CW, Ha, YJ, Kim, SY, et al.. Evaluation of the significance of pseudomyxoma peritonei patients based on the Peritoneal Surface Oncology Group International (PSOGI) classification. Asian J Surg 2021;44:848\u201353. https:\/\/doi.org\/10.1016\/j.asjsur.2021.01.012.","DOI":"10.1016\/j.asjsur.2021.01.012"},{"key":"2023060816410815274_j_pp-2023-0001_ref_024","doi-asserted-by":"crossref","unstructured":"Santullo, F, Pacelli, F, Abatini, C, Attalla El Halabieh, M, Fortunato, G, Lodoli, C, et al.. Cytoreduction and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin: a single center experience. Front Surg 2021;8:715119. https:\/\/doi.org\/10.3389\/fsurg.2021.715119.","DOI":"10.3389\/fsurg.2021.715119"},{"key":"2023060816410815274_j_pp-2023-0001_ref_025","doi-asserted-by":"crossref","unstructured":"Lopes, A, de Mello, ES, Mendoza Lopez, RV, Leonardi, PC, Ribeiro, U. Prognostic impact of pathology, cytoreduction, and tumor markers in pseudomyxoma peritonei. J Surg Res 2022;274:68\u201376. https:\/\/doi.org\/10.1016\/j.jss.2022.01.001.","DOI":"10.1016\/j.jss.2022.01.001"},{"key":"2023060816410815274_j_pp-2023-0001_ref_026","doi-asserted-by":"crossref","unstructured":"Milovanov, V, Sardi, A, Ledakis, P, Aydin, N, Nieroda, C, Sittig, M, et al.. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2015;41:707\u201312. https:\/\/doi.org\/10.1016\/j.ejso.2015.01.005.","DOI":"10.1016\/j.ejso.2015.01.005"},{"key":"2023060816410815274_j_pp-2023-0001_ref_027","doi-asserted-by":"crossref","unstructured":"Evans, T, Aziz, O, Chakrabarty, B, Wilson, MS, Malcomson, L, Lavelle, C, et al.. Long-term outcomes for patients with peritoneal acellular mucinosis secondary to low grade appendiceal mucinous neoplasms. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 2021;47:188\u201393. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.020.","DOI":"10.1016\/j.ejso.2020.10.020"},{"key":"2023060816410815274_j_pp-2023-0001_ref_028","unstructured":"Carr, NJ, Sobin, LH. Adenocarcinoma of the appendix. In: Bosman, FT, Carneiro, F, Hruban, RH, Theise, ND, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2010:122\u20135 pp."},{"key":"2023060816410815274_j_pp-2023-0001_ref_029","unstructured":"WHO Classification of Tumours Editorial Board. WHO classification of digestive system tumours. 5th ed. Lyon: IARC; 2019 Available from: https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Digestive-System-Tumours-2019."},{"key":"2023060816410815274_j_pp-2023-0001_ref_030","doi-asserted-by":"crossref","unstructured":"Ihemelandu, C, Sugarbaker, PH. Clinicopathologic and prognostic features in patients with peritoneal metastasis from mucinous adenocarcinoma, adenocarcinoma with signet ring cells, and adenocarcinoid of the appendix treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2016;23:1474\u201380. https:\/\/doi.org\/10.1245\/s10434-015-4995-0.","DOI":"10.1245\/s10434-015-4995-0"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0001\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0001\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T12:41:43Z","timestamp":1686228103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/pp-2023-0001\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5,8]]},"published-print":{"date-parts":[[2023,6,8]]}},"alternative-id":["10.1515\/pp-2023-0001"],"URL":"https:\/\/doi.org\/10.1515\/pp-2023-0001","relation":{},"ISSN":["2364-768X"],"issn-type":[{"value":"2364-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}